. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Cancer Immunol Immunother. 2019 Dec 5;69(1):95–102. doi: 10.1007/s00262-019-02442-5

Table 2:

Shift models for the DLT probabilities in Cohort 2.

Mel12.1 +	Model 1 (shift = 0) IFA < PolyICLC		Model 2 (shift =1) IFA < PoyICLC		Model 3 (shift = 2) IFA < PolyICLC
Mel12.1 +	CD27 (−)	CD27 (+)	CD27 (−)	CD27 (+)	CD27 (−)	CD27 (+)
IFA	0.15^{exp (a₁)}	0.15^{exp (a₁)}	0.15^{exp (a₂)}	0.24^{exp (a₂)}	0.15^{exp (a₃)}	0.33^{exp (a₃)}
Poly	0.24^{exp (a₁)}	0.24^{exp (a₁)}	0.24^{exp (a₂)}	0.33^{exp (a₂)}	0.24^{exp (a₃)}	0.43^{exp (a₃)}
Poly+IFA	0.33^{exp (a₁)}	0.33^{exp (a₁)}	0.33^{exp (a₂)}	0.43^{exp (a₂)}	0.33^{exp (a₃)}	0.53^{exp (a₃)}
	↓ Group C	↓ Group D	↓ Group C	↓ Group D	↓ Group C	↓ Group D
Mel12.1 +	Model 4 (shift = 0) IFA > PolyICLC		Model 5 (shift =1) IFA > PolyICLC		Model 6 (shift = 2) IFA > PolyICLC
	CD27 (−)	CD27 (+)	CD27 (−)	CD27 (+)	CD27 (−)	CD27 (+)
IFA	0.24^{exp (a₄)}	0.24^{exp (a₄)}	0.24^{exp (a₅)}	0.43^{exp (a₅)}	0.24^{exp (a₆)}	0.33^{exp (a₆)}
Poly	0.15^{exp (a₄)}	0.15^{exp (a₄)}	0.15^{exp (a₅)}	0.33^{exp (a₅)}	0.15^{exp (a₆)}	0.43^{exp (a₆)}
Poly+IFA	0.33^{exp (a₄)}	0.33^{exp (a₄)}	0.33^{exp (a₅)}	0.53^{exp (a₅)}	0.33^{exp (a₆)}	0.53^{exp (a₆)}
	↓ Group C	↓ Group D	↓ Group C	↓ Group D	↓ Group C	↓ Group D